Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 20 studies | 43% ± 14% | |
lung | 17 studies | 47% ± 17% | |
intestine | 11 studies | 48% ± 20% | |
eye | 10 studies | 40% ± 20% | |
brain | 10 studies | 27% ± 6% | |
kidney | 9 studies | 52% ± 10% | |
liver | 7 studies | 44% ± 23% | |
bone marrow | 5 studies | 44% ± 16% | |
pancreas | 4 studies | 53% ± 20% | |
placenta | 4 studies | 43% ± 20% | |
uterus | 4 studies | 58% ± 17% | |
lymph node | 4 studies | 51% ± 4% | |
breast | 4 studies | 37% ± 8% | |
heart | 3 studies | 27% ± 8% | |
adrenal gland | 3 studies | 44% ± 8% | |
esophagus | 3 studies | 46% ± 26% | |
prostate | 3 studies | 29% ± 4% | |
thymus | 3 studies | 61% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 4408.71 | 258 / 258 | 100% | 127.61 | 230 / 230 |
intestine | 100% | 4399.71 | 966 / 966 | 100% | 149.88 | 527 / 527 |
ovary | 100% | 3728.61 | 180 / 180 | 100% | 179.57 | 430 / 430 |
stomach | 100% | 3649.38 | 359 / 359 | 100% | 145.26 | 286 / 286 |
thymus | 100% | 5740.07 | 653 / 653 | 100% | 219.62 | 605 / 605 |
uterus | 100% | 3102.37 | 170 / 170 | 100% | 170.39 | 459 / 459 |
esophagus | 100% | 2978.23 | 1444 / 1445 | 100% | 96.08 | 183 / 183 |
brain | 100% | 6167.02 | 2640 / 2642 | 100% | 108.89 | 705 / 705 |
prostate | 100% | 4515.76 | 245 / 245 | 100% | 179.52 | 501 / 502 |
kidney | 100% | 8980.07 | 89 / 89 | 100% | 136.86 | 899 / 901 |
bladder | 100% | 2587.38 | 21 / 21 | 100% | 154.22 | 502 / 504 |
liver | 100% | 4367.65 | 225 / 226 | 100% | 132.47 | 406 / 406 |
skin | 100% | 3436.87 | 1807 / 1809 | 100% | 86.68 | 470 / 472 |
pancreas | 99% | 2346.80 | 326 / 328 | 100% | 123.31 | 178 / 178 |
breast | 100% | 2496.80 | 459 / 459 | 99% | 123.88 | 1110 / 1118 |
lung | 99% | 3011.29 | 573 / 578 | 100% | 105.95 | 1155 / 1155 |
lymph node | 0% | 0 | 0 / 0 | 100% | 216.03 | 29 / 29 |
spleen | 100% | 4415.73 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 125.03 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 212.65 | 1 / 1 |
muscle | 99% | 4684.62 | 798 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 2483.65 | 1321 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 6650.40 | 849 / 861 | 0% | 0 | 0 / 0 |
adipose | 99% | 2059.34 | 1186 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 79.68 | 76 / 80 |
peripheral blood | 87% | 2773.20 | 811 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001525 | Biological process | angiogenesis |
GO_0006091 | Biological process | generation of precursor metabolites and energy |
GO_1901030 | Biological process | positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
GO_1903214 | Biological process | regulation of protein targeting to mitochondrion |
GO_1904925 | Biological process | positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization |
GO_0006783 | Biological process | heme biosynthetic process |
GO_1903052 | Biological process | positive regulation of proteolysis involved in protein catabolic process |
GO_0032780 | Biological process | negative regulation of ATP-dependent activity |
GO_0072593 | Biological process | reactive oxygen species metabolic process |
GO_1903578 | Biological process | regulation of ATP metabolic process |
GO_0030218 | Biological process | erythrocyte differentiation |
GO_0001937 | Biological process | negative regulation of endothelial cell proliferation |
GO_0051882 | Biological process | mitochondrial depolarization |
GO_0051346 | Biological process | negative regulation of hydrolase activity |
GO_0005739 | Cellular component | mitochondrion |
GO_0032991 | Cellular component | protein-containing complex |
GO_0009986 | Cellular component | cell surface |
GO_0019899 | Molecular function | enzyme binding |
GO_0140260 | Molecular function | mitochondrial proton-transporting ATP synthase complex binding |
GO_0004857 | Molecular function | enzyme inhibitor activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0042030 | Molecular function | ATPase inhibitor activity |
GO_0051117 | Molecular function | ATPase binding |
GO_0005516 | Molecular function | calmodulin binding |
GO_0043532 | Molecular function | angiostatin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ATP5IF1 |
Protein name | ATPase inhibitor, mitochondrial (ATP synthase F1 subunit epsilon) (Inhibitor of F(1)F(o)-ATPase) (IF(1)) (IF1) ATPase inhibitor, mitochondrial (ATP synthase F1 subunit epsilon) |
Synonyms | ATPIF1 ATPI |
Description | FUNCTION: Endogenous F(1)F(o)-ATPase inhibitor limiting ATP depletion when the mitochondrial membrane potential falls below a threshold and the F(1)F(o)-ATP synthase starts hydrolyzing ATP to pump protons out of the mitochondrial matrix. Required to avoid the consumption of cellular ATP when the F(1)F(o)-ATP synthase enzyme acts as an ATP hydrolase. Indirectly acts as a regulator of heme synthesis in erythroid tissues: regulates heme synthesis by modulating the mitochondrial pH and redox potential, allowing FECH to efficiently catalyze the incorporation of iron into protoporphyrin IX to produce heme. . FUNCTION: Endogenous F(1)F(o)-ATPase inhibitor limiting ATP depletion when the mitochondrial membrane potential falls below a threshold and the F(1)F(o)-ATP synthase starts hydrolyzing ATP to pump protons out of the mitochondrial matrix. Required to avoid the consumption of cellular ATP when the F(1)F(o)-ATP synthase enzyme acts as an ATP hydrolase. .; FUNCTION: Indirectly acts as a regulator of heme synthesis in erythroid tissues: regulates heme synthesis by modulating the mitochondrial pH and redox potential, allowing fech to efficiently catalyze the incorporation of iron into protoporphyrin IX to produce heme. . |
Accessions | A0A0B4J230 ENST00000468425.2 ENST00000647074.2 [Q9UII2-1] ENST00000647380.1 [Q9UII2-3] ENST00000497986.5 [Q9UII2-2] ENST00000646781.1 ENST00000465645.1 [Q9UII2-3] ENST00000642464.1 [Q9UII2-2] ENST00000335514.10 [Q9UII2-1] Q9UII2 |